Brief: Ocumension Therapeutics - Revenue Increased Rmb54.5 Million For Six Months, Up 162.1%
26/08/2022 14:11
Ocumension Therapeutics 1477.HK :
* OCUMENSION THERAPEUTICS - REVENUE INCREASED RMB54.5
MILLION FOR
SIX MONTHS, UP 162.1%
* OCUMENSION THERAPEUTICS - HY ADJUSTED NET LOSS OF RMB76.9
MILLION VERSUS LOSS RMB109.2 MILLION
Source text for Eikon: ID:nHKS3Yk9VK
Further company coverage: 1477.HK
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application